LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival - 20/04/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 8 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival. |
• | The interaction between SLC16A1-AS1 and miR-141 in hepatocellular carcinoma was analyzed. |
Summary |
Background |
Long non-coding RNAs (LncRNAs) are broadly transcribed in the genome of human and animals, they play critical roles in cellular process, and participate in the progression of multiple diseases, including cancer. SLC16A1-AS1 is a tumor suppressive lncRNA in lung cancer. This study aimed to investigate the involvement of lncRNA SLC16A1-AS1 in hepatocellular carcinoma (HCC).
Method |
A total of 64 HCC patients were subjected to biopsy to obtain paired HCC and non-tumor tissues. Expression of SLC16A1-AS1 and miR-141 in paired tissues was determined by RT-qPCR. Correlations were analyzed by linear regression. Overexpression of SLC16A1-AS1 and miR-141 were achieved in HCC cells to explore the interactions between them. The methylation of the gene encoding miR-141 in HCC cells was detected by methylation-specific PCR (MSP). CCK-8 assay was performed for cell proliferation assay.
Results |
SLC16A1-AS1 was upregulated in HCC and its high expression levels predicted poor survival of HCC patients. Expression levels of miR-141 were lower in HCC patients and were inversely correlated with the expression levels of SLC16A1-AS1. In HCC cells, overexpression of SLC16A1-AS1 led to downregulation of miR-141, while overexpression of miR-141 did not regulate the expression of SLC16A1-AS1. In addition, overexpression of SLC16A1-AS1 led to increased methylation of miR-141. And overexpression of SLC16A1-AS1 attenuated the inhibitory effects of miR-141 on HCC cell proliferation.
Conclusion |
SLC16A1-AS1 is upregulated in HCC and predicts poor survival. In addition, SLC16A1-AS1 may downregulate miR-141 through methylation to promote cancer cell proliferation.
Le texte complet de cet article est disponible en PDF.Keywords : SLC16A1-AS1, Hepatocellular carcinoma, MiR-141, Survival, Methylation
Plan
Vol 45 - N° 2
Article 101490- mars 2021 Retour au numéro
Article précédent
- Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study
- Anthony Turpin, Thierry de Baere, Alexandra Heurgué, Karine Le Malicot, Isabelle Ollivier-Hourmand, Thierry Lecomte, Hervé Perrier, Julien Vergniol, David Sefrioui, Yves Rinaldi, Julien Edeline, Jean-Louis Jouve, Christine Silvain, Yves Becouarn, Barbara Dauvois, Mathieu Baconnier, Maryline Debette-Gratien, Gael Deplanque, Sébastien Dharancy, Côme Lepage, Mohamed Hebbar, PRODIGE 16 investigators Collaborators
- Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal
- Marie-Léa Gauci, Barouyr Baroudjian, Ulysse Bédérède, Charlotte Zeboulon, Julie Delyon, Clara Allayous, Isabelle Madelaine, Pirayeh Eftekhari, Matthieu Resche-Rigon, Nicolas Poté, Valerie Paradis, François Durand, Céleste Lebbé, Olivier Roux, Mohamed Bouattour, PATIO group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?